Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221230 · ClinicalTrials.gov registry record · Phase 2
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
A Phase 2 study, sponsored by Neumora Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT04221230: Completed Phase 2 study, sponsored by Neumora Therapeutics.
NCT04221230 is a Phase 2 study that has completed, run by Neumora Therapeutics. The registered enrollment target is 204 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04221230, a Phase 2 study, has completed, sponsored by Neumora Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
A proof of concept (POC) study evaluating the impact of NMRA-335140 (BTRX-335140) relative to placebo on symptoms of major depressive disorder (MDD) in adult participants with MDD and symptoms of anhedonia and anxiety following 8 weeks of double-blind treatment as assessed by the HAMD-17 Scale.
Primary Outcome
The HAMD-17 was a 17-item clinician-rated instrument used to assess the range of symptoms that were most frequently observed in participants with major depression. All items were scored on an ordinal scale between 0 and 4 (9 items) or 0 and 2 (8 items) of increasing severity. Each of 17 items was rated by clinician with rating of 0: absent, 1: doubtful to mild, 2: mild to moderate, 3: moderate to severe, and 4: very severe. A total score (0 to 52) was calculated by adding scores of all 17 items,
Interventions
- DRUG Placebo
- DRUG NMRA-335140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2020-01-03 |
| Est. Completion | 2022-06-23 |
| Phase | Phase 2 |
What the finished NCT04221230 record still lists
NCT04221230 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04221230 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04221230 about?
NCT04221230 is a clinical study titled "Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo". A proof of concept (POC) study evaluating the impact of NMRA-335140 (BTRX-335140) relative to placebo on symptoms of major depressive disorder (MDD) in adult participants with MDD and symptoms of anhedonia and anxiety following 8 weeks of double-blind treatment as assessed by the HAMD-17 Scale.
What is the current status of trial NCT04221230?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2020-01-03. Estimated completion is 2022-06-23.
What interventions are being tested in trial NCT04221230?
The interventions under investigation include: Placebo (DRUG), NMRA-335140 (DRUG).
Who is sponsoring clinical trial NCT04221230?
This trial is sponsored by Neumora Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04221230's enrollment target sits among peer trials
204 299th of 2000 higher than 1,700 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI